1-9 of 9
John F. Seymour
Close
Sort by
Journal Articles

Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

Clinical Trials & Observations
Stephan Stilgenbauer, Eugen Tausch, Andrew W. Roberts, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebastian Böttcher, Arnon P. Kater, Yanwen Jiang, Michelle Boyer, Relja Popovic, Majd T. Ghanim, Michael Moran, Wendy J. Sinai, Xifeng Wang, Nabanita Mukherjee, Brenda Chyla, William G. Wierda, John F. Seymour
Journal: Blood Advances
Blood Adv (2024) 8 (8): 1992–2004.
https://doi.org/10.1182/bloodadvances.2023011741
Published: 2024
Includes: Supplemental data
Journal Articles

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon

Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Casan, Piers Blombery, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Philip A. Thompson, Mary A. Anderson
Journal: Blood Advances
Blood Adv (2024) 8 (6): 1439–1443.
https://doi.org/10.1182/bloodadvances.2023011327
Published: 2024
Includes: Supplemental data
Journal Articles

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance

Piers Blombery, Ella R. Thompson, Thomas E. Lew, Ing Soo Tiong, Rory Bennett, Chan Y. Cheah, Katharine Louise Lewis, Sasanka M. Handunnetti, Chloe Pek Sang Tang, Andrew Roberts, John F. Seymour, Constantine S. Tam
Journal: Blood Advances
Blood Adv (2022) 6 (20): 5589–5592.
https://doi.org/10.1182/bloodadvances.2022008325
Published: 2022
Includes: Supplemental data
Journal Articles

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Clinical Trials & Observations
Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4553–4557.
https://doi.org/10.1182/bloodadvances.2022007812
Published: 2022
Journal Articles

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i

John F. Seymour
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1365–1370.
https://doi.org/10.1182/bloodadvances.2019001205
Published: 2022
Journal Articles

Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors

Ella R. Thompson, Tamia Nguyen, Yamuna Kankanige, John F. Markham, Mary Ann Anderson, Sasanka M. Handunnetti, Rachel Thijssen, Paul Sung-Hao Yeh, Constantine S. Tam, John F. Seymour, Andrew W. Roberts, David A. Westerman, Piers Blombery
Journal: Blood Advances
Blood Adv (2022) 6 (2): 503–508.
https://doi.org/10.1182/bloodadvances.2021006211
Published: 2022
Includes: Supplemental data
Journal Articles

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition

Clinical Trials & Observations
Thomas E. Lew, Victor S. Lin, Edward R. Cliff, Piers Blombery, Ella R. Thompson, Sasanka M. Handunnetti, David A. Westerman, Bryone J. Kuss, Constantine S. Tam, David C. S. Huang, John F. Seymour, Andrew W. Roberts, Mary Ann Anderson
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4054–4058.
https://doi.org/10.1182/bloodadvances.2021005083
Published: 2021
Includes: Supplemental data
Journal Articles

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Clinical Trials & Observations
Joanne E. Davis, Sasanka M. Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W. Roberts, John F. Seymour, Constantine S. Tam, David S. Ritchie, Rachel M. Koldej
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4849–4859.
https://doi.org/10.1182/bloodadvances.2020002810
Published: 2020
Includes: Supplemental data
Journal Articles

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Clinical Trials & Observations
Thomas E. Lew, Mary Ann Anderson, Victor S. Lin, Sasanka M. Handunnetti, Neil A. Came, Piers Blombery, David A. Westerman, Meaghan Wall, Constantine S. Tam, Andrew W. Roberts, John F. Seymour
Journal: Blood Advances
Blood Adv (2020) 4 (1): 165–173.
https://doi.org/10.1182/bloodadvances.2019000864
Published: 2020
Includes: Supplemental data